Legend Biotech

LEGN

Market cap $6.13B

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal gastrointestinal condition.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Legend Biotech Corporation (NASDAQ:LEGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Ying Huang - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.

SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025.

New Jersey based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with strong efficacy and double-digit sequential revenue growth, but Legend only receives a 50% revenue share outside China. Despite >$1bn cash and operational improvements, Legend remains unprofitable, with heavy GAAP losses and apparently no formal guidance for 2025.

Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants Alan S. Bash - President of CARVYKTI® Caroline LeCates Paul - Associate Director of Investor Relations Jessie Yeung - Interim CFO, Principal Financial Officer & Principal Accounting Officer Mythili Koneru - Chief Medical Officer Ying Huang - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division James John Shin - Deutsche Bank AG, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Justin Reid Zelin - BTIG, LLC, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Leonid Timashev - RBC Capital Markets, Research Division Mitchell Swaroop Kapoor - H.C.

Key Inflation Data in Focus.

SOMERSET, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2025 unaudited financial results and key corporate highlights.

Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.